Milestone Pharmaceuticals Inc. (MIST)
NASDAQ: MIST · Real-Time Price · USD
0.3650
-0.1550 (-29.81%)
At close: Nov 16, 2026, 4:00 PM EST
0.3700
+0.0050 (1.37%)
Pre-market: Nov 17, 2026, 7:43 AM EST

Milestone Pharmaceuticals Stock Forecast

MIST's stock price has decreased by -81.75% in the past year and price targets may not have had time to catch up.

Stock Price Forecast

According to 7 analysts polled by S&P Global, Milestone Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $3.86. The average 1-year stock price forecast is 956.71% higher than the current stock price, while the lowest is $1.00 (+173.97%) and the highest is $6.00 (+1,543.84%).

Price Target: $3.86 (+956.71%)
Analyst Consensus: Strong Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$1.00$3.86$4.00$6.00
Change+173.97%+956.71%+995.89%+1543.8%

Analyst Ratings

The average analyst rating for Milestone Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart
RatingMay '26Jul '26Aug '26Sep '26Oct '26Nov '26
Strong Buy445555
Buy111111
Hold111111
Sell000000
Strong Sell000000
Total667777

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
TD Cowen
TD Cowen
Buy
Maintains
$8 → $5
BuyMaintains$8 → $5+1,269.86%Nov 16, 2026
Piper Sandler
Piper Sandler
Buy
Maintains
$7 → $3
BuyMaintains$7 → $3+721.92%Nov 16, 2026
H.C. Wainwright
H.C. Wainwright
Buy
Reiterates
$8 → $6
BuyReiterates$8 → $6+1,543.84%Nov 16, 2026
Wells Fargo
Wells Fargo
Buy
Maintains
$7 → $4
BuyMaintains$7 → $4+995.89%Nov 13, 2026
Raymond James
Raymond James
Buy
Maintains
$6 → $5
BuyMaintains$6 → $5+1,269.86%Oct 20, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
4.88M
from 1.55M
Increased by 215.89%
Revenue Next Year
12.55M
from 4.88M
Increased by 157.01%
EPS This Year
-0.79
from -0.75
EPS Next Year
-0.61
from -0.79
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
15.00M5.00M1.00M-1.55M4.88M
Revenue Growth
--66.67%-80.00%--215.89%
Gross Profit
15.00M5.00M1.00M-1.55M4.27M
Gross Margin
100.00%100.00%100.00%-100.00%87.40%
Operating Income
-43.07M-59.64M-61.10M-42.10M-62.14M-102.05M
Net Income
-42.85M-58.39M-59.69M-41.52M-63.06M-109.31M
EPS
-----0.75-0.79
Free Cash Flow
------81.50M
No. Analysts
-----7
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High5.4M
Avg4.9M
Low3.3M

Revenue Growth

Revenue Growth202620272028
High
249.3%
Avg
215.9%
Low
113.5%

EPS Forecast

EPS202620272028
High-0.69
Avg-0.79
Low-0.85

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-